This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by de Jonge, H. J.M. Articles by de Bont, E. S.J.M. Search for Related Content PubMed PubMed Citation Articles by de Jonge, H. J.M. Articles by de Bont, E. S.J.M.

Endogenous Vascular Endothelial Growth Factor-C Expression Is Associated with Decreased Drug Responsiveness in Childhood Acute Myeloid Leukemia

Authors' Affiliations: ¹ Division of Pediatric Oncology/Hematology, Department of Pediatrics, Beatrix Children's Hospital and ² Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; ³ Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, the Netherlands; ⁴ Department of Pediatric Oncology/Hematology, University Children's Hospital, Münster, Germany; and ⁵ Department of Pediatric Oncology/Hematology, Medical School Hannover, Hannover, Germany

Requests for reprints: Eveline S.J.M. de Bont, Division of Pediatric Oncology/Hematology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands. Phone: 31-50-3614213; E-mail: e.de.bont{at}bkk.umcg.nl.

Purpose: We hypothesized that downstream effects of endogenous vascular endothelial growth factor (VEGF)/VEGF receptor signaling on acute myelogenous leukemia (AML) cell survival resulted in increased in vitro cellular drug resistance and a longer time to kill most leukemic cells in vivo upon drug exposure.

Experimental Design: In primary AML cells from pediatric patients, VEGFA and VEGFC mRNA expression and in vitro cellular resistance to nine cytotoxic drugs were studied. As in vivo equivalents for in vitro drug resistance, in vivo AML blast reduction upon drug exposure, measured as blast cell reduction on day 15 in the bone marrow and as time in days from diagnosis to complete remission (CR) were used.

Results: Increased endogenous VEGFC levels significantly correlated with increased in vitro resistance for six typical AML drugs in primary AML cells from pediatric patients. Patients with >5% blasts on day 15 showed a 12.9-fold increase in the median VEGFC level compared with patients with 5% blasts (P = 0.002). Time to reach CR was studied using linear regression analysis with VEGFC, age at diagnosis, sex, treatment protocol, FAB type, cytogenetic risk profile, and WBC counts as variables. There was a significant positive independent association between VEGFC levels and time to CR (b = 6.02, SE = 1.58, P 0.0001, n = 72).

Conclusions: These results suggest for the first time that higher endogenous VEGFC levels of AML cells are related to decreased in vitro and in vivo drug responsiveness.